The Food and Drug Administration (FDA) has approved Moderna’s updated COVID-19 jabs, the company announced.
“Today we announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Applications for the 2026-2027 formulas for Spikevax® (COVID-19 Vaccine, mRNA) and mNEXSPIKE® (COVID-19 Vaccine, mRNA), containing the JN.1-lineage XFG subvariant of SARS-CoV-2 to help prevent COVID-19,” Moderna stated.
“The updated formula for Spikevax is now approved for individuals 6 months through 64 years of age with at least one underlying condition placing them at high risk for severe outcomes from COVID-19, and all adults 65 years of age and older,” Moderna stated in a press release.
“mNEXSPIKE, Moderna’s latest COVID-19 vaccine, is approved for individuals 12 through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19, and all adults 65 years of age and older,” it continued.
ABC News shared further:
“COVID-19 remains a serious public health threat, responsible for up to 2.3 million outpatient visits and 250,000 hospitalizations in the U.S. last year alone,” said Stéphane Bancel, Chief Executive Officer of Moderna.
“Our updated COVID-19 vaccines help protect those at high risk of severe disease, and we are proud to help ensure Americans have access to the latest protection against currently circulating SARS-CoV-2 strains this respiratory virus season,” he added.
More from The New York Times:
What are your thoughts?

TAP HERE TO ADD YOUR VOTE
This is a Guest Post from our friends over at 100 Percent Fed Up. View the original article here.
Continue reading...
[ H/T WLT Report ]